These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2225704)

  • 1. Suppression of deferoxamine mesylate treatment-induced side effects by coadministration of isoniazid in a patient with Alzheimer's disease subject to aluminum removal by ionspecific chelation.
    Kruck TP; Fisher EA; McLachlan DR
    Clin Pharmacol Ther; 1990 Oct; 48(4):439-46. PubMed ID: 2225704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A predictor for side effects in patients with Alzheimer's disease treated with deferoxamine mesylate.
    Kruck TP; Fisher EA; McLachlan DR
    Clin Pharmacol Ther; 1993 Jan; 53(1):30-7. PubMed ID: 8422739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron and aluminum in Alzheimer's disease.
    Di Lorenzo F; Di Lorenzo B
    Neuro Endocrinol Lett; 2013; 34(6):504-7. PubMed ID: 24378455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deferoxamine for aluminum toxicity in dialysis patients.
    Hernandez P; Johnson CA
    ANNA J; 1990 Jun; 17(3):224-8. PubMed ID: 2357118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intramuscular desferrioxamine in patients with Alzheimer's disease.
    Crapper McLachlan DR; Dalton AJ; Kruck TP; Bell MY; Smith WL; Kalow W; Andrews DF
    Lancet; 1991 Jun; 337(8753):1304-8. PubMed ID: 1674295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of ultrafiltration and chromatography to assess aluminum speciation in serum after deferoxamine administration.
    Canteros-Picotto A; Fernández-Martín JL; Cannata-Andía JB
    Am J Kidney Dis; 2000 Nov; 36(5):969-75. PubMed ID: 11054353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of intramuscular and intraperitoneal deferoxamine for aluminum chelation.
    Molitoris BA; Alfrey PS; Miller NL; Hasbargen JA; Kaehney WD; Alfrey AC; Smith BJ
    Kidney Int; 1987 Apr; 31(4):986-91. PubMed ID: 3586503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity.
    Sprague SM; Corwin HL; Wilson RS; Mayor GH; Tanner CM
    Arch Intern Med; 1986 Oct; 146(10):2063-4. PubMed ID: 3767553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention and treatment of aluminum toxicity including chelation therapy: status and research needs.
    Yokel RA; Ackrill P; Burgess E; Day JP; Domingo JL; Flaten TP; Savory J
    J Toxicol Environ Health; 1996 Aug; 48(6):667-83. PubMed ID: 8772805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal by desferrioxamine of tau protein aggregates following two days of treatment in aluminum-induced neurofibrillary degeneration in rabbit: implications for clinical trials in Alzheimer's disease.
    Savory J; Huang Y; Wills MR; Herman MM
    Neurotoxicology; 1998 Apr; 19(2):209-14. PubMed ID: 9553957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
    Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):41-7. PubMed ID: 18274982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
    Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E; Orofino N; Roghi A; Duca L; Poggiali E; Fraquelli M; Zanaboni L; Cappellini MD
    Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aluminum as a pathogenic factor in senile dementia of the Alzheimer type: ion specific chelation.
    Kruck TP; McLachlan DR
    Prog Clin Biol Res; 1989; 317():1155-67. PubMed ID: 2690090
    [No Abstract]   [Full Text] [Related]  

  • 15. Desferrioxamine and Alzheimer's disease: video home behavior assessment of clinical course and measures of brain aluminum.
    McLachlan DR; Smith WL; Kruck TP
    Ther Drug Monit; 1993 Dec; 15(6):602-7. PubMed ID: 8122302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aluminum chelation: chemistry, clinical, and experimental studies and the search for alternatives to desferrioxamine.
    Yokel RA
    J Toxicol Environ Health; 1994 Feb; 41(2):131-74. PubMed ID: 8301696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of vitamin B6 on the blood isoniazid concentration and its role in the regulation of the functional state of central nervous system in dogs].
    Bondarev IM; Tregubov IuG; Klebanova AA
    Probl Tuberk; 1974; 65(4):73-7. PubMed ID: 4835661
    [No Abstract]   [Full Text] [Related]  

  • 18. Desferrioxamine in the treatment of aluminum overload.
    Ackrill P; Day JP
    Clin Nephrol; 1985; 24 Suppl 1():S94-7. PubMed ID: 3842106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
    Vichinsky E; Torres M; Minniti CP; Barrette S; Habr D; Zhang Y; Files B;
    Am J Hematol; 2013 Dec; 88(12):1068-73. PubMed ID: 23946212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.